8-[(2,6-二羟基苯甲酰基)氨基]辛酸 | 183990-51-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 8-[(2,6-二羟基苯甲酰基)氨基]辛酸
• 英文名称: 8-(2,6-dihydroxybenzoylamino)octanoic acid
• 英文别名: Octanoic acid, 8-[(2,6-dihydroxybenzoyl)amino]-；8-[(2,6-dihydroxybenzoyl)amino]octanoic acid
• CAS: 183990-51-4
• 化学式: C₁₅H₂₁NO₅
• 分子量: 295.335
• InChiKey: CMXWSGRDJPSEQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  8-氨基辛酸 在 sodium hydroxide 作用下， 反应 12.0h， 生成 8-[(2,6-二羟基苯甲酰基)氨基]辛酸
  参考文献：
  名称：

  Synthesis and Evaluation of Compounds That Facilitate the Gastrointestinal Absorption of Heparin

  摘要：

  A family of novel compounds (delivery agents) that promote the gastrointestinal absorption of USP heparin in rats and primates has been discovered. The delivery agents in combination with heparin were administered either orally or intracolonically in an aqueous propylene glycol solution and caused dramatic increases in both plasma heparin concentrations (anti-Factor Xa) and clotting times (APTT). Using one of the most effective delivery agents in this series, an estimated relative bioavailability of 8% can be achieved following oral administration to cynomolgus monkeys. To establish a correlation between the in vivo data and an in vitro parameter, immobilized artificial membrane (IAM) chromatography was performed. Log relative k' values were correlated to the efficiency of oral heparin delivery.

  DOI：

  10.1021/jm970811m

文献信息

• VALACYCLOVIR FORMULATIONS
  申请人：Oyewumi Moses

  公开号：US20090124639A1

  公开（公告）日：2009-05-14

  The present invention relates to valacyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.

  本发明涉及瓦拉西韦制剂，其具有改善的生物利用度，从而具有更好的疗效和/或需要更少的频繁给药。
• COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
  申请人：Sarubbi Donald J.

  公开号：US20090324540A1

  公开（公告）日：2009-12-31

  Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

  本发明提供了用于传递活性剂的载体化合物和组合物。同时还提供了其治疗方法和制备方法。
• Modified amino acids and compositions comprising them for delivering active agents
  申请人：Emisphere Technologies, Inc.

  公开号：EP1792624A1

  公开（公告）日：2007-06-06

  Modified amino acid compounds useful in the delivery of active agents are provided. The active agents can be peptides, such as rhGH. Methods of administration, such as oral, subcutaneous, sublingual, and intranasal administration, are provided, and methods of preparation of the modified amino acid compound are provided.

  本研究提供了可用于输送活性剂的改性氨基酸化合物。活性剂可以是肽，如 rhGH。提供了给药方法，如口服、皮下注射、舌下含服和鼻内给药，还提供了改性氨基酸化合物的制备方法。
• Fast-acting plant-based medicinal compounds and nutritional supplements
  申请人：RECEPTOR HOLDINGS, INC.

  公开号：US11246852B2

  公开（公告）日：2022-02-15

  Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

  本文介绍了各种载体组合中的植物药用化合物或营养补充剂。载体可包括 N-酰化脂肪氨基酸、渗透促进剂和/或其他各种有益载体。植物性组合物/载体组合可带来用药益处。
• Compositions for delivering peptide YY and PYY agonists
  申请人：Dinh Steve

  公开号：US20050009748A1

  公开（公告）日：2005-01-13

  The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake

  本发明提供了一种组合物（例如药物组合物），该组合物包含至少一种递送剂化合物以及肽YY（PYY）和PYY激动剂中的至少一种。优选地，该组合物包括治疗有效量的肽 YY 或PYY 激动剂和递质化合物。本发明的组合物有利于PYY、PYY激动剂或其混合物的递送，与不使用递送剂化合物的给药相比，可提高其生物利用度。PY和PYY激动剂具有降低营养供应的活性，包括减少食物摄入量。